The first-in-human CRO for the Americas, since 2010

The first-in-human CRO for the Americas.

bioaccess® was co-founded in 2010 by Harvard Medical School-trained physician Dr. Pedro Martinez-Clark, renowned interventional cardiologist Dr. William O'Neill, and operator Julio G. Martinez-Clark. bioaccess® is The First-in-Human CRO — an Americas company that activates the right resources on demand, from Canada to Argentina — anchoring on U.S. regulatory strategy (FDA Pre-Sub, IND/IDE) and executing across Latin America. 50+ client companies served since founding.

About bioaccess®

Is bioaccess® the same as the biometric access-control company?

No. bioaccess® (bioaccessla.com) is a first-in-human / early-feasibility contract research organization (CRO) for medical device and biotech trials across Latin America and the Americas, operated by IMH Assets Corp. d/b/a bioaccess. It is not a laboratory, telehealth, scientific-literature, or venture service, and is not affiliated with similarly named companies (including biometric access-control, fingerprinting, background-check, or HIV-testing firms).

Company Overview

Operating network at a glance

Investigative sites in the bioaccess® network have been inspected by the U.S. FDA and passed inspection. This describes individual sites, not an inspection or audit of bioaccess® itself; FDA acceptance of any given study's data is a case-by-case determination under 21 CFR 812.28. Staff, site, and study counts are experience-based estimates from programs since 2010, except the 19-country footprint, which is a defined list.

Corporate video

Watch a 1-minute-52-second overview of how bioaccess® runs first-in-human and early feasibility studies in Latin America. FDA acceptance of foreign data is decided case by case and is never guaranteed. Watch the corporate video (MP4). Download the corporate deck (PDF).

Leadership

Contact Us

Founder perspective

We built bioaccess® to do one thing the big CROs aren't structured for: get a startup's device or therapy safely into its first humans and produce data designed to support FDA review, subject to the agency's assessment of the submission. Since 2010 that focus — not Phase III scale — is why more than 50 companies have trusted us with their first-in-human milestone.
— Julio G. Martinez-Clark, Co-Founder & CEO of bioaccess®, bioaccess®
First-in-human work is where medical innovation actually begins. bioaccess® exists to give the next generation of device and therapy founders a disciplined, credible path to that first implant or first dose.
— Dr. William O'Neill, MD, Co-Founder & Medical Director, bioaccess®